Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Zentalis Pharmaceuticals ( (ZNTL) ) is now available.
On January 22, 2025, Zentalis Pharmaceuticals announced a strategic restructuring, including a workforce reduction of approximately 40%, to support the late-stage development of its WEE1 inhibitor product candidate, azenosertib. The restructuring aims to extend the company’s cash runway beyond the anticipated 2026 data readout from the DENALI Part 2 study. The company expects to incur one-time costs of approximately $7.0–8.0 million due to the workforce reduction, which is expected to be largely completed by the second quarter of 2025. This move is intended to efficiently allocate resources to advance azenosertib’s development and potentially bring it to market for patients with gynecological malignancies, thereby solidifying Zentalis’ position in the oncology therapeutics market.
More about Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics that target fundamental biological pathways in cancers. The company’s lead product candidate, azenosertib, is a WEE1 inhibitor being evaluated for use in advanced solid tumors, including ovarian cancer, and exhibits potential as a first-in-class treatment.
YTD Price Performance: -20.0%
Average Trading Volume: 1,569,114
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $158.2M
Learn more about ZNTL stock on TipRanks’ Stock Analysis page.